HER2

The development of On-Target Antibody is mainly to solve the problem of On-target toxicity in immunotherapy. For antibodies that activate the body's immune system, such as CTLA-4 and 4-1BB antibodies, they can systematically activate the body's immune system, resulting in excessive immune response. In addition, solid tumors are also expressev various targets which are also on the surface of normal cells, so antibodies can indiscriminately bind targets on tumor cells and targets on normal cells, resulting in side effects. On-Target Antibody takes advantage of the enrichment of some small molecules such as ATP in the tumor microenvironment, and activates the antibody by using the small molecule as a medium, so that the antibody is specifically activated only in the tumor.

"On-target" tumor antigen binding

ATP-mediated antibody engineering technology

Cooperation Seeking

ERBB2